Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM: PRecIsion in SCLC Via a Multicohort Study
NCT06769126Phase 2Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of saruparib, ceralasertib and monalizumab in small cell lung cancer (SCLC) (6 cohorts), sponsored by SWOG Cancer Research Network. Primary endpoints: Screen success rate up to 3 years and Progression-Free Survival up to 3 years. Started Nov 2025; status: recruiting.
02
Drugs
saruparibceralasertibmonalizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06769126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769126.